Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Persistent Endometrial Carcinoma”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05870761
What this trial is testing

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Who this might be right for
Recurrent Endometrial Serous Adenocarcinoma
Casey Cosgrove 8
Testing effectiveness (Phase 2)Ended earlyNCT02059265
What this trial is testing

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Who this might be right for
Endometrial Clear Cell AdenocarcinomaOvarian Clear Cell CystadenocarcinomaRecurrent Fallopian Tube Carcinoma+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04251416
What this trial is testing

Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Who this might be right for
Endometrial Carcinoma
Yale University 50
Testing effectiveness (Phase 2)Study completedNCT00006089
What this trial is testing

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaERBB2 Gene AmplificationRecurrent Uterine Corpus Carcinoma+2 more
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Study completedNCT00071929
What this trial is testing

Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT04814108
What this trial is testing

Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Who this might be right for
Uterine Serous Carcinoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 92
Testing effectiveness (Phase 2)Study completedNCT02725268
What this trial is testing

Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

Who this might be right for
Endometrial Neoplasms
Millennium Pharmaceuticals, Inc. 241
Testing effectiveness (Phase 2)Study completedNCT00027690
What this trial is testing

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Recurrent Uterine Corpus Carcinoma
National Cancer Institute (NCI) 56
Early research (Phase 1)UnknownNCT01454479
What this trial is testing

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Who this might be right for
Recurrent Endometrial Cancer
Hung-Hsueh Chou 24
Testing effectiveness (Phase 2)Study completedNCT00729586
What this trial is testing

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial CarcinomaRecurrent Uterine Corpus CarcinomaStage IIIA Uterine Corpus Cancer+5 more
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)Study completedNCT00301964
What this trial is testing

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Recurrent Endometrial Carcinoma
National Cancer Institute (NCI) 56
Testing effectiveness (Phase 2)Study completedNCT01642082
What this trial is testing

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Adenocarcinoma+6 more
Gynecologic Oncology Group 28
Testing effectiveness (Phase 2)Study completedNCT00122343
What this trial is testing

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 45
Testing effectiveness (Phase 2)Study completedNCT03015129
What this trial is testing

Durvalumab With or Without Tremelimumab in Endometrial Cancer

Who this might be right for
Endometrial CancerEndometrial CarcinosarcomaEndometrial Carcinoma+2 more
Memorial Sloan Kettering Cancer Center 80
Testing effectiveness (Phase 2)Study completedNCT01225887
What this trial is testing

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous Adenocarcinoma+6 more
Gynecologic Oncology Group 37
Testing effectiveness (Phase 2)Study completedNCT00462826
What this trial is testing

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Recurrent Endometrial Carcinoma
National Cancer Institute (NCI) 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT03660826
What this trial is testing

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Who this might be right for
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00820898
What this trial is testing

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+1 more
Gynecologic Oncology Group 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03835819
What this trial is testing

Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Who this might be right for
Endometrial Cancer
Dana-Farber Cancer Institute 18
Testing effectiveness (Phase 2)Looking for participantsNCT03832361
What this trial is testing

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Who this might be right for
Endometrial Cancer
Alessandro Santin 50
Next Page
288